The serum GLP-1 levels were partially lower in L
Dosage is escalated monthly according to the standard titration schedule up to the target maintenance level of 2.4 mg once weekly
tirzepatide and high-dose GLP-1 RA, did not account for lower, yet clinically relevant, s.c
Beyond pancreatic effects, GLP-1R agonists exert widespread extra-pancreatic benefits, attributed to the extensive distribution of GLP-1R in different organs, including gastrointestinal tract, kidneys, liver, skeletal and smooth muscle, neural tract, adipose tissue, and the cardiovascular system, where they are expressed in endothelial cells, vascular smooth muscle, cardiomyocytes, and different inflammatory cells [20], underpinning the synthetic GLP-1 and GLP-1RAs associated cardiovascular benefits observed in clinics [21]